Calmasol-440, solution for infusion for cattle, sheep and pigs

Authorised

- Boric acid
- Magnesium chloride hexahydrate
- Calcium gluconate monohydrate

Product identification

Medicine name:
Calmasol-440, solution for infusion for cattle, sheep and pigs
Calmafusion vet 380 mg/ml + 60 mg/ml + 50 mg/ml infusjonsvæske, oppløsning til storfe, sau og gris

Active substance:
Boric acid
Magnesium chloride hexahydrate
Calcium gluconate monohydrate

Target species:
Cattle
Sheep
Pig

Route of administration:
Intravenous use

Product details

Active substance and strength:

Boric acid
50.00 milligram(s) / 1.00 millilitre(s)

Magnesium chloride hexahydrate
60.00 milligram(s) / 1.00 millilitre(s)

Calcium gluconate monohydrate
380.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for infusion

Withdrawal period by route of administration:

Intravenous use:

- **Cattle**
  - Meat and offal. 0 day
  - Milk. 0 hour
- **Sheep**
  - Meat and offal. 0 day
  - Milk. 0 hour
- **Pig**
  - Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QA12AX

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:
Valid

Authorised in:
Norway

Package description:
Graduated polypropylene bottle, closed with a bromobutyl rubber stopper and secured with an aluminium cap. 12x500 ml.
Graduated polypropylene bottle, closed with a bromobutyl rubber stopper and secured with an aluminium cap. 1x500 ml.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Interchemie Werken De Adelaar Eesti AS

Marketing authorisation date:
17/12/2019

Manufacturing sites for batch release:
Interchemie Werken De Adelaar Eesti AS

Responsible authority:
Norwegian Medical Products Agency

Authorisation number:
19-12901

Date of authorisation status change:
17/12/2019

Reference member state:

Estonia

Procedure number:
EE/V/0104/001

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Finland France Germany Greece Hungary Iceland Ireland Italy Latvia Malta Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 25/07/2025
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.